- Home
- ACHV
as 05-09-2025 4:00pm EST
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Upcoming Earnings Alert:
Get ready for potential market movements as Achieve Life Sciences Inc. ACHV prepares to release earnings report on 13 May 2025.
| Founded: | N/A | Country: | Canada |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 72.5M | IPO Year: | N/A |
| Target Price: | $14.33 | AVG Volume (30 days): | 178.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.84 - $5.59 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Achieve Life Sciences Inc. (ACHV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Stewart Richard Alistair | ACHV | Chieve Executive Officer | Mar 17 '25 | Buy | $2.86 | 10,000 | $28,598.00 | 60,876 | |
| Oki Mark K | ACHV | Chief Financial Officer | Mar 17 '25 | Buy | $2.89 | 10,000 | $28,887.00 | 10,000 |
Latest Achieve Life Sciences Inc. News
ACHV Breaking Stock News: Dive into ACHV Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025
TipRanks
17 days ago
Achieve Life Sciences announces publication of results from Phase 3 ORCA-3 trial
MT Newswires
18 days ago
Achieve Life Sciences Expects to File New Drug Application in US for Smoking Cessation Medication
GlobeNewswire
18 days ago
Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine
Insider Monkey
2 months ago
Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory
Zacks Small Cap Research
2 months ago
ACHV: 2Q:25 NDA Submission
Thomson Reuters StreetEvents
2 months ago
Q4 2024 Achieve Life Sciences Inc Earnings Call
GuruFocus.com
2 months ago
Achieve Life Sciences Inc (ACHV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
Compare ACHV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACHV Achieve Life Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.